FDA
Pharma

Vaccine makers facing increased volatility, uncertainty at FDA

The FDA's decision to not review Moderna's flu vaccine application is another indication of the volatility and unpredictability of the U.S. regulator.
Kevin Dunleavy Feb 13, 2026 11:12am
Stockpile inventory supply chain

Lilly builds sizable store of orforglipron ahead of FDA verdict

Feb 13, 2026 2:40pm
pills drug costs money prices cash
Favicon Fierce Healthcare

Trump administration restarts its efforts to pilot 340B rebates

Feb 13, 2026 1:00pm
Vertex

Vertex sets lofty $500M revenue goal for new products in '26

Feb 13, 2026 12:02pm
Astellas Pharma Izervay Partners in Protection campaign

Astellas Izervay campaign casts HCPs as ‘Partners in Protection’

Feb 13, 2026 11:57am
Food and Drug Administration

Regulatory tracker: Amgen's Uplizna wins gMG nod in Europe

Feb 13, 2026 11:00am
More News

Bayer keeps diners in the dark to shed light on heart health

Feb 13, 2026 10:55am

Novartis to seek full IgAN nod for Vanrafia despite ph. 3 miss

Feb 13, 2026 10:52am
Fierce Biotech

Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg

Feb 13, 2026 10:10am

PTC withdraws US approval filing for Duchenne drug Translarna

Feb 13, 2026 10:05am